This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Q2 #1: Discussing the current treatment landscape for Alzheimer's including Eisai/Biogen's Leqembi and Eli Lilly's recently approved Kisunla (donanemab).

Ticker(s): BIIB, ESAIY

Who's the expert?

 Marc L. Gordon, MD, is chief of neurology at Zucker Hillside Hospital and professor of neurology and psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. He received his BA and MA from the State University of New York at Buffalo and his MD from Columbia University, College of Physicians & Surgeons. He completed his neurology residency training and a fellowship in neuropsychopharmacology at Albert Einstein College of Medicine in 1990. Dr. Gordon is a diplomate of the American Board of Psychiatry and Neurology and a fellow of the American Academy of Neurology.

Interview Goal
.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.